Johnson & Johnson (JNJ)
The desk's stance
On our research list, not on the slate.
What the company does
The AAA-rated healthcare fortress: Innovative Medicine blockbusters (Darzalex, Tremfya) and MedTech tracking toward $100B+ annual revenue in 2026, absorbing Stelara biosimilar entry with barely a dent in growth.
In short: Innovative medicines and medical devices. Category: Diversified Pharma and MedTech Giant. Sector: Healthcare, Drug Manufacturers - General.
G-Street Value and Score
G-Street Value: $242.44, computed Oct 18, 2026 (confidence: medium).
How we got there: 70% analyst leg $260.66 (4 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $199.92 (17.08× fwd EPS anchored to healthcare multiples).
G-Street Score: 47 out of 100 (Weak).
- Top-line growth & guidance: 7 of 32
- Margin power: 8 of 15
- Revenue visibility & quality: 5 of 11
- Profitability & balance sheet: 19 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 3 of 12
Our current thesis
Updated Oct 14, 2026
The thesis
- Tremfya, Darzalex, and Carvykti drive resilient high-single-digit operational growth in Innovative Medicine.
- Ottava soft-tissue robotic surgical platform expands MedTech's high-margin runway into the late 2020s.
- Consistent $15B-plus annual free cash flow comfortably anchors the 60-plus year dividend growth track record.
Risks
- Stelara biosimilar competition created an approximate 690 bps drag on pharmaceutical segment revenue.
- Forward P/E of 21.6x trades at an expansive premium over peers ABBV and MRK.
- Unsettled talc liabilities and M&A charges generate recurring GAAP net income volatility.
What we're watching
- Commercial hospital rollout and initial surgeon adoption metrics for the Ottava robotic system.
- Court proceedings and cash outflow schedules surrounding the proposed talc bankruptcy settlement.
- Share price support consolidation within the $245 to $252 post-earnings trading range.
Latest
JNJ rebounded 2.1% to $253.91 following its Q3 2026 print ($25.40B revenue, +5.9% YoY; adjusted EPS $2.59), as management lifted full-year revenue guidance to $101.0B–$101.4B and adjusted EPS to $11.05–$11.15. Sequential top-line growth is flattening near $25.4B while Stelara biosimilar erosion generated an approximate 690 bps drag on Innovative Medicine. Multiple brokerages trimmed price targets into the $275–$280 range following the release, citing softer MedTech trends and persistent legal charges.
Key numbers
As of Oct 16, 2026: market cap $615.9B · revenue growth +5.9% year over year · gross margin 67.8% · net margin 16.2% · forward P/E 21.8.
Analyst price targets
Published analyst targets we could trace to a named source.
- Morgan Stanley, Overweight: $292 target (October 2026). Source: marketscreener.com
- Wells Fargo, Overweight: $275 target (October 2026). Source: benzinga.com
- RBC Capital, Outperform: $280 target (October 2026). Source: benzinga.com
- JPMorgan, Neutral: $285 target (September 2026). Source: marketbeat.com
On the Gainz Lab maps
Who it does business with
- AbbVie competes with Johnson & Johnson — Immunology turf. Skyrizi and Rinvoq vs Tremfya and Darzalex across psoriasis, arthritis, and IBD — the highest-grossing non-obesity turf war in pharma.